Aurora Cannabis Announces Appointment of Faris El Refaie as Executive Vice President, Global Commercial
EDMONTON, AB – September 9, 2026 /PRNewswire/ — Aurora Cannabis Inc. (NASDAQ: ACB), a leading global medical cannabis company based in Canada, has announced the appointment of Faris El Refaie as Executive Vice President, Global Commercial, effective September 28, 2026. El Refaie brings 25 years of experience in the biopharmaceutical industry and will oversee Aurora’s global commercial functions, focusing on expanding the company’s medical cannabis market strategy.
In his new role, El Refaie will be responsible for aligning Aurora’s global portfolio, enhancing customer engagement, and accelerating commercial growth in Canada, Europe, Australia, New Zealand, and other international markets.
Miguel Martin, Executive Chairman and CEO of Aurora, expressed excitement about El Refaie’s addition to the team, emphasizing his extensive experience in driving commercial growth and market leadership in the biopharmaceutical sector.
El Refaie’s background includes leadership roles at JAMP Pharma Group, GSK, and AstraZeneca, where he developed substantial commercial expertise. His experience will help Aurora strengthen its presence in key markets as the company aims to provide high-quality medical cannabis to more patients globally.
Aurora Cannabis is committed to technical advancements and patient care, and El Refaie’s appointment reflects the company’s ongoing effort to enhance its global commercial platform.
For more information about Aurora Cannabis, please visit www.auroramj.com and follow us on social media platforms.
Forward-Looking Statements: This announcement may contain forward-looking statements regarding future business developments and market strategies. Readers are advised to review the associated risks and uncertainties.
